BLBei Liu

Bei Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bei Liu has a total of 98 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Identification of Potential Core Genes Associated With Air Pollution Exposure‑Related Acute Myeloid Leukemia Via Integrated Network Toxicology and Molecular Docking Analysis

    by Xin Gao, Qianwen Hu, Shanshan He, Bei Liu

    Background: Air pollutants increase acute myeloid leukemia (AML) risk, but the underlying mechanisms are unclear. Objective :This study aims to identify key genes and pathways linking air pollutants to AML, supporting disease prevention and targeted research. Methods: Shared targets of air pollutants and AML were retrieved from public databases. Protein–protein interaction (PPI) network, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment, and TCGA survival analyses were performed to screen hub genes. Molecular docking validated the binding affinity of key targets. Results: A total of 157 common target genes for air pollutants and AML were identified. KEGG and GO enrichment analyses indicated that these targets were mainly related to inflammatory responses, endocrine system regulation, and cell signal transduction. CytoHubba topological analysis combined with TCGA survival analysis identified 5 hub genes: CASP9, HDAC1, CASP3, EGFR, and AR. Molecular docking showed that AR had the highest binding affinity with Naphthalene, and CASP9 had the highest binding affinity with Naphthalene, suggesting that these targets may potentially induce diseases through them. Conclusion: These findings provide new ideas for clarifying the mechanism of the role of environmental exposure in the occurrence of leukemia and for conducting environmental prevention and control.

  • Open Access

    Retrospective evaluation of venetoclax-based regimen in newly diagnosed and relapsed/refractory acute myeloid leukemia: Efficacy determinants, survival outcomes, and model validation

    by Anan Wang, Haiping Liang, Chongchong Ren, Yin Wang, Jiangang Guo, Jiajing Li, Xiaoda Yu, Bei Liu

    Treatment response, survival outcomes, and factors related to venetoclax (VEN)-based therapy were assessed in patients with acute myeloid leukemia (AML), including newly diagnosed AML (ND-AML) and relapsed/refractory AML (R/R AML). We also developed a model to predict composite complete remission (CRc) after the first treatment cycle. This retrospective study included 216 patients with AML who received VEN-based regimens at the First Hospital of Lanzhou University between March 2020 and May 2025. Treatment response, overall survival (OS), and factors related to CRc and OS were evaluated. A multivariable model for CRc was developed and internally validated using 1,000 bootstrap resamples. Of the 216 patients, 165 had ND-AML and 51 had R/R AML. CRc was achieved in 74.5% and 39.2% of patients, respectively. In ND-AML, failure to achieve CRc, older age, and NF1 mutation were independently associated with shorter OS. In R/R AML, a lower pretreatment white blood cell count and a higher bone marrow blast percentage were associated with CRc, whereas failure to achieve CRc was associated with higher mortality. The final six-predictor model included AML status, age, bone marrow blast percentage, platelet count, Eastern Cooperative Oncology Group (ECOG) performance status, and TET2 mutation. Its apparent area under the receiver operating characteristic curve (AUC) was 0.841 (95% confidence interval, 0.785–0.897). The fixed CRc score yielded time-dependent OS AUCs of 0.788 at 6 months and 0.695 at 12 months. The model may be useful for estimating early treatment response, although external validation is needed before routine clinical application.

  • Open Access

    Targeting the Glutamine Transporter SLC1A5 Enhances Sensitivity of Acute Myeloid Leukemia to MLN4924

    by Yin Wang, Yuancheng Guo, Xiao Tang, Yu Zhu, Haiping Liang, Yali Zhang, Bei Liu

    Background/Objectives: Acute myeloid leukemia (AML) remains a hematologic malignancy with poor prognosis. The neddylation inhibitor MLN4924 has demonstrated potent anti-leukemic activity in preclinical models, yet its clinical translation faces significant challenges. The aim of this study was to explore combination therapy strategies that could further enhance MLN4924’s anti-leukemia potential. Methods: AML cell lines used in this study were Kasumi-1 and MOLM-13. Cell viability was assessed using CCK-8 assays. mRNA and protein expression levels were determined through RT-qPCR and Western blot, respectively. Flow cytometry was employed to analyze surface markers (SLC1A5, CD11b, CD14, CD16), mitochondrial membrane potential (JC-1), and apoptosis (Annexin V-FITC/PI). In vivo efficacy was validated using an NCG mouse xenograft model. Transcriptomic profiling was performed to explore the potential mechanism by which MLN4924 in combination with V9302 inhibits leukemia. Results: Treatment with MLN4924 significantly upregulated key glutamine metabolic proteins, GLUL and the glutamine transporter SLC1A5, in AML cells. Knockdown of SLC1A5 significantly enhanced AML cell sensitivity to MLN4924. The combination of MLN4924 and the SLC1A5 inhibitor V9302 synergistically inhibited AML cell proliferation, induced monocytic differentiation, and promoted apoptosis. Transcriptomic analysis revealed that this combination therapy prominently suppressed the tricarboxylic acid (TCA) cycle. Conclusions: Neddylation inhibition induces compensatory upregulation of glutamine metabolism in AML. Co-targeting neddylation and glutamine transporter SLC1A5 synergistically exerts anti-leukemic effects, at least in part through disruption of the TCA cycle. This combination represents a novel and effective therapeutic strategy against AML.


  • Venetoclax combined with ML385 overcomes chemotherapy resistance in acute myeloid leukemia by modulating Nrf2/ARE-mediated oxidative stress

    by Long Zhao, Yuancheng Guo, Jinli Jian, Xiao Tang, Shujuan An, Yujie Niu, Bei Liu

    This study aimed to investigate the potential of Venetoclax combined with ML385 to overcome drug resistance in leukemia cells and the related mechanisms. Analysis of Nrf2 expression and its prognostic significance in AML was performed utilizing the GEO and GEPIA2 databases. Bone marrow specimens were collected from newly diagnosed AML patients to evaluate Nrf2 expression levels and assess their correlation with established risk stratification and clinical prognosis. Two doxorubicin-resistant leukemia cell lines were established. Subsequently, stable Nrf2-knockdown cell lines were generated via lentiviral transduction. Cellular proliferation and apoptosis were analyzed. Levels of reactive oxygen species (ROS) and glutathione (GSH), alongside the expression of oxidative stress-related and apoptosis-related genes and proteins, were quantified. Furthermore, the effects of Venetoclax combined with ML385 on proliferation, apoptosis, ROS levels, and GSH levels were subsequently investigated in these doxorubicin-resistant cell lines. Mechanistically, the impact of the drug combination on oxidative stress and the PI3K/AKT signaling pathway was explored. Nrf2 was up-regulated in AML and predicted poor prognosis. In doxorubicin-resistant AML cells, oxidative-stress genes were elevated. Silencing Nrf2 inhibited proliferation, induced apoptosis, lowered GSH, raised ROS, increased pro-apoptotic BAX and Caspase-3, and decreased anti-apoptotic Bcl-2. Combining the venetoclax with ML385 significantly suppressed proliferation and induced apoptosis in drug-resistant leukemia cells. Mechanistically, this dual-targeting regimen concurrently attenuated both the Nrf2-mediated antioxidant defense and the pro-survival PI3K/AKT signaling axis, which collectively underpin its enhanced anti-leukemic efficacy. This study demonstrates venetoclax combined with ML385 overcomes chemotherapy resistance in acute myeloid leukemia by modulating Nrf2/ARE-mediated oxidative stress.These findings reveal a novel mechanism and a promising therapeutic strategy. Graphical Abstract Schematic of Venetoclax and ML385 overcoming doxorubicin resistance in AML via modulation of Nrf2/ARE-mediated oxidative stress.KEAP1, Kelch-like ECH-associated protein 1; NRF2, nuclear factor erythroid 2-related factor 2; ARE, antioxidant response element; Maf, musculoaponeurotic fibrosarcoma; NQO1, NADPH-quinone Dehydrogenase 1; HMOX1, Heme oxygenase 1;ROS, Reactive oxygen species;GSH, Glutathione.


  • Open Access

    Identification and validation of mitochondrial and programmed cell death-related prognostic markers in pediatric acute myeloid leukemia

    by Xiaoyan Hu, Qiang Zhao, Wei Deng, Yonghuan Li, Bei Liu

    Background: Pediatric acute myeloid leukemia (AML) is characterized by poor prognosis and low survival rates following recurrence. While mitochondria and programmed cell death (PCD) are implicated in various diseases, their role in pediatric AML remains poorly understood. Identifying prognostic genes associated with PCD and mitochondrial function could enhance therapeutic approaches. Methods: Transcriptomic data and gene sets were sourced from public databases. Differentially expressed genes (DEGs) that intersected with PCD-related genes (PCD-RGs) and mitochondrial-related genes (mito-RGs) were selected as candidate genes. Regression analyses were performed to identify prognostic genes, which were then used to develop and validate a prognostic model. A nomogram was constructed, followed by functional analysis, immune microenvironment assessment, molecular regulatory network investigation, drug sensitivity profiling, and clinical validation through RT-qPCR. Results: Twenty-six candidate genes were identified, with three—PDHA1, OGG1, and OPA1—confirmed as potential prognostic markers through regression analyses. The prognostic model demonstrated robustness in both internal and external validations, and the nomogram exhibited good predictive power. Pathway enrichment analysis highlighted the involvement of DNA replication and epithelial-mesenchymal transition, alongside 14 differentially abundant immune cells (p < 0.05). Molecular network analysis indicated that hsa-miR-199a-5p regulates PDHA1 and OGG1. Drug sensitivity profiling identified potential therapeutic agents, including SB505124_1194. RT-qPCR validation confirmed consistent expression patterns for the prognostic genes. Conclusions: PDHA1, OGG1, and OPA1 were identified as potential prognostic markers for pediatric AML, providing valuable insights for the development of targeted therapeutic strategies. However, further validation in larger and more diverse clinical cohorts is still required to confirm its clinical applicability.

  • Open Access

    MLN4924 Suppresses Acute Myeloid Leukemia Progression by LINC01128-Driven Epigenetic Reactivation of TRIM58

    by Yuancheng Guo, Jinli Jian, Xiao Tang, Shujuan An, Long Zhao, Run Chen, Weiqing Ma, Bei Liu

    Purpose: The aim of this study was to elucidate the molecular mechanism by which MLN4924 affects the progression of acute myeloid leukemia (AML) by regulating TRIM58 DNA methylation. Patients and Methods: Gene expression was analyzed by RT-qPCR and Western blot, while methylation changes were assessed via Methylation-sensitive restriction enzyme-quantitative PCR. Differentially expressed lncRNAs were identified through RNA sequencing. Subcellular localization was determined via nuclear-cytoplasmic fractionation-PCR. Protein-DNA/RNA interactions were analyzed by chromatin immunoprecipitation and RNA immunoprecipitation, respectively. In vivo experiments were conducted using a xenograft model, with tumor protein expression evaluated by immunohistochemistry. Results: TRIM58 downregulation in AML correlated with promoter hypermethylation, reversible by MLN4924 treatment. Functional studies demonstrated TRIM58 mediated MLN4924-induced apoptosis through AKT pathway inhibition. While MLN4924 upregulated the tumor-suppressive lncRNA LINC01128, its overexpression recapitulated TRIM58-mediated anti-leukemic effects, including expansion arrest, apoptosis induction, and BAX/BCL-2 axis modulation. Mechanistically, nuclear-localized LINC011128 functionally interacted with DNMT1 to mediate TRIM58 promoter demethylation, establishing an epigenetic regulatory axis. Rescue experiments revealed TRIM58 knockdown attenuated MLN4924’s suppression of AKT phosphorylation and associated pro-apoptotic effects. Conclusion: In this study, we show that MLN4924 can upregulate LINC01128, which binds to and segregates DNMT1, thereby inhibiting methylation modification of the TRIM58 and ultimately suppressing AML.


  • Open Access

    Clinical Characteristics and Outcomes of Acute Myeloid Leukemia Patients Harboring NPM1/FLT3-ITD/DNMT3A Triple Mutations and the Potential Prognostic Value of GNG4

    by Yujie Niu, Xingchun Luo, Xiaoxiao Yang, Yuancheng Guo, Xiao Tang, Long Zhao, Jinli Jian, Bei Liu

    Introduction: Nucleophosmin 1 ( NPM1 ), FMS-like tyrosine kinase 3-internal tandem duplication ( FLT3-ITD ), and de novo methyl transferase 3 A ( DNMT3A ) triple-mutated acute myeloid leukemia (AML) represents a distinct entity with poor outcomes. Methods: We explored the gene mutation spectrum and clinical characteristics of 165 AML patients retrospectively, particularly comparing patients with NPM1/FLT3-ITD/DNMT3A triple-mutations and those without. Results: Our results demonstrated significantly elevated white blood cell counts ( P < 0.001), bone marrow blast percentages ( P = 0.037), and platelet counts ( P = 0.007) in the triple-mutated cohort (6.7%) compared to the non-triple-mutated patients. Furthermore, all triple-mutated cases were classified as the M4/M5 subtype of the French-American-British classification ( P = 0.017). Although no significant difference in complete remission rates was observed between the groups after initial treatment, the median overall survival for triple-mutated AML patients was only 4 months. Using the Gene Expression Omnibus (GEO) database and bioinformatics, we compared AML NPM1 mut FLT3-ITD mut DNMT3A mut and AML NPM1 mut FLT3-ITD mut DNMT3A wt . A total of 246 AML patients from the GEO dataset were included to evaluate the expression profiles of differentially expressed genes. The guanine nucleotide-binding protein subunit γ 4 ( GNG4 ) was differentially expressed between AML NPM1 mut FLT3-ITD mut DNMT3A mut and AML NPM1 mut FLT3-ITD mut DNMT3A wt , which had the most adjacent nodes among hub genes. The prognostic value of GNG4 was further validated in AML patient samples through qRT-PCR. Conclusion: Clinical validation indicated a substantial downregulation of GNG4 in AML NPM1 mut FLT3-ITD mut DNMT3A mut compared to AML NPM1 mut FLT3-ITD mut DNMT3A wt patients. Thus, GNG4 may play a role in the low survival rate of AML NPM1 mut FLT3-ITD mut DNMT3A mut patients, offering novel insights into the prognosis, therapeutic targets, and prognostic evaluation of AML.


  • Open Access

    Integrated transcriptome profiling and in vitro analysis reveals MLN4924’s role in inducing ferroptosis in acute myeloid leukemia

    by Jinli Jian, Yuancheng Guo, Xiao Tang, Long Zhao, Bei Liu

    While ferroptosis induction emerges as a therapeutic strategy for solid tumors, its role in acute myeloid leukemia (AML) remains unexplored. This study aimed to investigate the role of MLN4924 in modulating ferroptosis and its molecular targets in AML. Transcriptome sequencing and bioinformatics analyses were performed to identify MLN4924 potential targets in ferroptosis. First, ferroptosis-related phenotypic assays were conducted, including assays of reactive oxygen species (ROS), glutathione (GSH), malondialdehyde (MDA), and Fe2+ levels. Second, cell viability assays were carried out with the combination of MLN4924 and ferroptosis inducers (Erastin, Sorafenib). Third, rescue experiments were used the ferroptosis inhibitor Ferrostatin-1 after MLN4924 treatment. In vivo efficacy was evaluated in NOD/SCID mice bearing AML xenografts treated with MLN4924, followed by tumor tissue analysis of GSH and Fe2+ levels, immunohistochemistry (IHC), and Western blotting for SLC7A11/GPX4 axis components. Transcriptome sequencing and bioinformatics analyses identified SLC7A11 and GPX4 as key MLN4924 target genes, both of which are glutathione-related proteins. MLN4924 significantly suppressed SLC7A11 and GPX4 expression, decreased GSH activity, and increased ROS, Fe2+, and MDA levels. Ferroptosis inducers (Erastin, Sorafenib) further enhanced the antileukemic activity of MLN4924, and ferroptosis inhibitor Ferrostatin-1 partially reversed this toxicity. In vivo, MLN4924 reduced tumor burden, accompanied by SLC7A11/GPX4 downregulation and Fe2+ accumulation in xenografts. This study provides the first evidence that MLN4924 triggers ferroptosis in AML by inhibiting the SLC7A11/GPX4 axis. These findings establish MLN4924 as a ferroptosis sensitizer through synergistic effects with ferroptosis inducers, supporting its therapeutic potential in AML.


  • Open Access

    Significant changes in gut microbiota and SCFAs among patients with newly diagnosed acute myeloid leukemia

    by Shujuan An, Xia Gong, Long Zhao, Jinli Jian, Yuancheng Guo, Xiaoxiao Yang, Hongjia Sun, Yang Li, Bei Liu

    The purpose of this study was to identify whether the gut microbiota and metabolites of newly diagnosed acute myeloid leukemia (AML) patients displayed specific characteristic alterations and whether these changes could be used as potential biomarkers for predicting the disease. Notably, the gut microbiota and metabolites of AML patients exhibited significant structural and quantitative alterations at the time of their initial diagnosis. Beneficial bacteria, including Faecalibacterium, Collinsella, Lacticaseibacillus, and Roseburia, as well as butyric acid and acetic acid, were found to be considerably reduced in newly diagnosed AML patients. In contrast, Enterococcus and Lactobacillus, especially Enterococcus, were significantly enriched. Further investigation indicated that Enterococcus could serve as a potential intestinal marker, showing a strong negative correlation with the levels of acetic and butyric acid. Importantly, assays aimed at identifying AML demonstrated that Enterococcus, butyric acid, and acetatic acid exhibited excellent predictive effectiveness. Colonizing Enterococcus from patients were isolated for pathogen investigation, which revealed that these bacteria possess several strong virulence factors and multiple drug-resistance gene characteristics. Therefore, we speculate that the increase of Enterococcus may contribute to the development and progression of AML.